Clinically, by blocking this interaction with anti-PD-1 and anti-PD-L1 antibodies, we can not only promote the proliferation of T cells but also restore their cytotoxic responses against tumor cells [16, 17]. The gene discussed is CD274; the disease is neoplasm.